Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer

There is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in tw...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Que, Yi, Wang, Juan, Zhu, Jia, Li, Na, Huang, Junting, Lu, Suying, Sun, Feifei, Zhang, Lian, Zhen, Zijun, Zhang, Li, Cai, Ruiqing, Guo, Haixia, Sun, Xiaofei, Zhang, Yizhuo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290852/
https://ncbi.nlm.nih.gov/pubmed/34295326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.647733
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia